Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS AMPLIFICATION
(
ENST00000256078.10 )
KRAS AMPLIFICATION ( ENST00000256078.10 ) - Associated Disease
- endometrial cancer
- Source Database
- CIViC Evidence
- Description
- In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplification were highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (P<0.001). Amplification of KRAS maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.2–5.8, P=0.02). In contrast, presence of KRAS mutation did not influence prognosis (P=0.67)
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5836
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/592
- Rating
- 3
- Evidence Type
- Prognostic
- Disease
- Endometrial Cancer
- Evidence Direction
- Supports
- Evidence Level
- B
- Clinical Significance
- Poor Outcome
- Pubmed
- 23099803
Drugs